VNDA vs VRAX

Vanda Pharmaceuticals Inc. vs Virax Biolabs Group Limited — Valuation Comparison 2026

VNDA

Biotechnology
Vanda Pharmaceuticals Inc.
Quality
6.3
out of 10
Value Trap
26
LOW
Price
$6.64
Last close
Models
9/13
Active
VS

VRAX

Biotechnology
Virax Biolabs Group Limited
Quality
1.6
out of 10
Value Trap
6
SAFE
Price
$0.21
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType VNDA Fair ValueVNDA Upside VRAX Fair ValueVRAX Upside
Bayesian DCF Intrinsic $4.15 -37.6% $0.06 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.57 -91.9% $0.16 -25.8%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $8.53 +28.5% $0.28 +125.8%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VNDA vs VRAX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VNDA vs VRAX — Which Stock Is More Undervalued?

VNDA scores higher with a 6.3/10 quality rating vs VRAX's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vanda Pharmaceuticals Inc. (VNDA) and Virax Biolabs Group Limited (VRAX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VNDA currently trades at $6.64 with a QOC of 6.3/10, while VRAX trades at $0.21 with a QOC of 1.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).